PMS2 and cancer: Germline variants play a role in 8.5%–10% of all pediatric cancer with the prevalence of certain genes such as TP53, APC, NF1, PMS2, RB1, and RUNX1. The increasing implementation and availability of genetic testing lead to the opportunity to identify the risk of cancer and early detection of tumors with the aim of reducing mortality and morbidity (21).